Press Releases

Arch Therapeutics Receives CE Mark Approval for AC5™ Topical Hemostat in Europe
Arch Therapeutics Receives Marketing Clearance from the US FDA Related to the AC5® Topical Gel Supply Chain
Arch Therapeutics, Inc. to Present at the New York City based Investor Summit on March 25th-26th
Arch Therapeutics Novel Self-Assembling Agent for Use in Endoscopic Procedures to be Presented at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 2020 Annual Meeting on April 2, 2020
Arch Therapeutics to Provide Corporate Update at the 2020 LD Micro Virtual Investor Conference
Arch Therapeutics to Provide Corporate Update at Biotech Showcase™ 2020 on January 13th, 2020
Arch Therapeutics Announces $2.5 Million Registered Direct Offering
Arch Therapeutics Provides Corporate Update at the 2nd Annual LD Micro Big Apple Conference in Manhattan, NY
Arch Therapeutics to Provide Corporate Update at the H.C. Wainwright 21st Annual Global Investment Conference
Arch Therapeutics Announces AC5 Self-Assembling Peptide Technology Platform Demonstrates Antimicrobial Activity in Two Studies and Provides CE Marking Status Update for AC5™ Topical Hemostat
RSS
Show All